BioSight Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

BioSight General Information

Description

Developer of novel peptide-based drugs designed to provide therapeutics for hematological malignancies and disorders. The company's drugs target and release therapeutic enzymes inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments, enabling patients to receive safe and effective treatment for life-threatening diseases.

Contact Information

Website
www.biosight-pharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3 Hayarden Street, Airport City
  • P.O.B 1083
  • Lod 7019802
  • Israel
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Ayala Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3 Hayarden Street, Airport City
  • P.O.B 1083
  • Lod 7019802
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioSight Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 18-Oct-2023 Completed Clinical Trials - Phase 2
6. Reverse Merger 06-Jul-2021 Cancelled Clinical Trials - Phase 2
5. Later Stage VC (Series C) 02-Dec-2020 Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private 15-Jun-2017 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 16-May-2016 Completed Clinical Trials - Phase 2
2. Later Stage VC 30-Jul-2008 $3.5M $3.5M Completed Clinical Trials - Phase 2
1. Early Stage VC Completed Pre-Clinical Trials
To view BioSight’s complete valuation and funding history, request access »

BioSight Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferred B1
Preferred B
To view BioSight’s complete cap table history, request access »

BioSight Patents

  • 77

    Total Documents Applications and Grants

  • Total Patents Families

  • 27

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

BioSight Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023233410-A1 Crystalline form of aspacytarabine intermediate Inactive 02-Jun-2022
WO-2023228177-A1 Compositions comprising aspacytarabine and additional compounds, and use thereof Inactive 22-May-2022
WO-2023175622-A1 Crystalline forms of aspacytarabine Inactive 17-Mar-2022
AU-2022392831-A1 Cytarabine-amino acid based prodrug for the treatment of cancer Inactive 21-Nov-2021
CA-3239219-A1 Cytarabine-amino acid based prodrug for the treatment of cancer Pending 21-Nov-2021 A61K47/542
To view BioSight’s complete patent history, request access »

BioSight Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioSight Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arkin Capital Asset Manager Minority
Angel (individual) Minority
BioTelemetry Corporation Minority
Costal Holdings Venture Capital Minority
Cradle Fund Accelerator/Incubator Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

BioSight FAQs

  • When was BioSight founded?

    BioSight was founded in 1999.

  • Where is BioSight headquartered?

    BioSight is headquartered in Lod, Israel.

  • What is the size of BioSight?

    BioSight has 10 total employees.

  • What industry is BioSight in?

    BioSight’s primary industry is Drug Discovery.

  • Is BioSight a private or public company?

    BioSight is a Private company.

  • What is BioSight’s current revenue?

    The current revenue for BioSight is .

  • How much funding has BioSight raised over time?

    BioSight has raised $62.5M.

  • Who are BioSight’s investors?

    Arkin Capital, , BioTelemetry, Costal Holdings, and Cradle Fund are 5 of 15 investors who have invested in BioSight.

  • When was BioSight acquired?

    BioSight was acquired on 18-Oct-2023.

  • Who acquired BioSight?

    BioSight was acquired by Ayala Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process